Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12056.145 | 0.9640 | 0.9143 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12056.145 | 0.9884 | 0.9724 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12056.145 | 0.9504 | 0.8819 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12056.145 | 0.9102 | 0.7873 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12056.145 | 0.9807 | 0.9538 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12056.145 | 0.9816 | 0.9560 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12178.145 | 1.0048 | 1.0156 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12178.145 | 0.9880 | 0.9611 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12178.145 | 1.0142 | 1.0466 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12178.145 | 1.0043 | 1.0141 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12178.145 | 0.9214 | 0.7499 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12178.145 | 1.0524 | 1.1739 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12178.145 | 0.9375 | 0.8000 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12178.145 | 1.1141 | 1.3857 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12178.145 | 1.0657 | 1.2188 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12291.17 | 0.9947 | 0.9811 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12291.17 | 0.9868 | 0.9531 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12291.17 | 0.9824 | 0.9373 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12291.17 | 0.8660 | 0.5459 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12291.17 | 0.8475 | 0.4871 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12291.17 | 0.9952 | 0.9828 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12291.17 | 0.8632 | 0.5370 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12291.17 | 0.8968 | 0.6458 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12291.17 | 1.0040 | 1.0144 | 0.5585 | |
| BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10696.145 | 0.9815 | 0.8903 | 0.3316 |